Skip to main content

Displaying 41 - 60 of 165

Sep15

Open Commission Meeting – September 15, 2021

Agenda items: Proposed Policy Statement on Privacy Breaches by Health Apps and Connected Devices, Non-HSR Reported Acquisitions by Select Technology Platforms, 2010-2019: An FTC Study, Proposed...

Illumina, Inc., and GRAIL, Inc.

The Federal Trade Commission filed an administrative complaint and authorized a federal court lawsuit to block Illumina’s $7.1 billion proposed acquisition of Grail—a maker of a non-invasive, early detection liquid biopsy test that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing. Illumina is the only provider of DNA sequencing that is a viable option for these multi-cancer early detection, or MCED, tests in the United States.

The complaint alleges the proposed acquisition will diminish innovation in the U.S. market for MCED tests, which could be used to detect up to 50 types of cancer. Most of these types of cancer are not screened for at all today, and the MCED test could save millions of lives around the world. The trial is scheduled to begin on Aug. 24, 2021. On May 20, 2021, the FTC authorized staff to dismiss its federal court complaint for Preliminary Injunction and Temporary Restraining Order.

Type of Action
Federal
Last Updated
Case Status
Closed